BioCentury
ARTICLE | Clinical News

Vargatef nintedanib: Phase I data

October 8, 2012 7:00 AM UTC

A dose-escalation Phase I trial in 45 patients with advanced solid tumors showed that 10-40 mg afatinib given daily on a continuous or intermittent schedule (every other week) in combination with twice-daily 150 mg nintedanib in a 28-day cycle led to 2 partial responses and 27 cases of stable disease. The MTDs were twice-daily 150 mg nintedanib in combination with 40 mg afatinib given daily on the intermittent schedule or in combination with 30 mg afatinib given daily on the continuous schedule. The most common adverse events were diarrhea, asthenia, nausea, vomiting and transaminase elevations. ...